Eli Lilly and Company (LLY)
| Market Cap | 196.20B |
| Revenue (ttm) | 24.54B |
| Net Income (ttm) | 6.19B |
| Shares Out | 907.63M |
| EPS (ttm) | 6.79 |
| PE Ratio | 30.47 |
| Forward PE | 25.06 |
| Dividend | $2.96 |
| Dividend Yield | 1.43% |
| Trading Day | March 5 |
| Last Price | $206.92 |
| Previous Close | $200.54 |
| Change ($) | 6.38 |
| Change (%) | 3.18% |
| Day's Open | 201.25 |
| Day's Range | 200.88 - 207.67 |
| Day's Volume | 3,876,160 |
| 52-Week Range | 114.87 - 217.09 |
European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for Eli Lilly and Co's (NYSE: LLY) bamlanivimab alone, and baml...
INDIANAPOLIS, March 5, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) h...
INDIANAPOLIS, March 5, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that The Lancet has published data fr...
Eli Lilly (LLY) closed the most recent trading day at $200.54, moving -0.72% from the previous trading session.
Eli Lilly & Co (NYSE: LLY) has reported positive results from another Phase 3 trial evaluating tirzepatide in Type 2 diabetics. The dual GIP/GLP-1 agonist beat Novo Nordisk A/S's (NYSE: NVO) s...
INDIANAPOLIS, March 4, 2021 /PRNewswire/ -- Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses compared to injectable semaglutide 1 mg in adults wi...
Eli Lilly and Co (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announces top-line results from Phase 3 BRAVE-AA2 study evaluating baricitinib 2-mg and 4-mg in adults with severe alopecia a...
INDIANAPOLIS, March 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today top-line results from BRAVE-AA2, a Phase 3 study evaluating the efficacy ...
When the operating income margin keeps on expanding, it typically means that the company's management is successful in implementing policies that keep expenses well below profits.
Lilly (LLY) reported earnings 30 days ago. What's next for the stock?
Eli Lilly (LLY) closed at $204.89 in the latest trading session, marking a +0.52% move from the prior day.
SHANGHAI, China, Feb. 27, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development a...
After the rise of 10-year yields terrified investors, the indices “reverse rotated” back into the Nasdaq and out of the Dow. Make the most of this market with today's top buys, from Q.ai's Art...
The U.S. government has agreed to purchase a minimum of 100,000 doses of Eli Lilly and Co's (NYSE: LLY) COVID-19 antibody therapy combining bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-C...
The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals.
COLUMBIA, Md. and INDIANAPOLIS, Feb. 25, 2021 /PRNewswire/ -- Welldoc, Inc., and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc'...
INDIANAPOLIS, Feb. 24, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Cowen and Company 41st Annual Health Care Conference on Thursday, March 4, 2021. Daniel Sk...
Even investors that don't own the stocks must have had their interest piqued about the goings-on with GameStop Corp. (NYSE:GME), AMC Entertainment Holdings Inc. (NYSE:AMC) and Express Inc. (NY...
The FDA encourages companies to evaluate the impact of COVID-19 virus variants on the efficacy or performance of their COVID-19 vaccines, tests and medicines.
Eli Lilly CEO: We see a path to have an Alzheimer's disease-modifying drug
Eli Lilly CEO Dave Ricks how the drugmaker has worked for decades to find a way to treat Alzheimer's disease. The company says a Phase 2 trial of donanemab reveals that the drug can slow progr...
Eli Lilly And Co (NYSE: LLY) announced a licensing deal Thursday with smaller biopharma Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) that helps Lilly lock horns with the Sanofi SA (NASDAQ: SNY-D...
INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., Feb. 18, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a global exclusive ...
Investors should always be on the lookout for ways to diversify and bolster their portfolios. One great place to start is with large cap stocks that pay solid dividends.
Indicative of investors' enthusiasm for new biotechs, the average gain in share price for the top 10 companies of the sector that went public in 2020 now tops 100%.
Eli Lilly And Co (NYSE: LLY) have announced topline results from two Phase 3 studies, SURPASS-3 and SURPASS-5, evaluating Tirzepatide in adults with type 2 diabetes. Data showed that Tirzepati...
INDIANAPOLIS, Feb. 17, 2021 /PRNewswire/ -- Tirzepatide led to significant A1C and body weight reductions from baseline in adults with type 2 diabetes in Eli Lilly and Company's (NYSE: LLY) SU...
INDIANAPOLIS, Feb. 17, 2021 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Kimberly H. Johnson as a new member, effective February 16, 2021. As a membe...
Eli Lilly and Co.'s (NYSE:LLY) 28% increase in share price in 2020 was the highest among members of big [harma. According to an Evaluate Pharma report, the gain pushed the company's market val...
INDIANAPOLIS, Feb. 11, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021. Ilya ...
These biotech companies may be among the winners of the coronavirus treatment race -- if all goes well in clinical trials.
FDA grants EUA to Eli Lilly's (LLY) COVID-19 antibody cocktail. FDA also authorizes shortened infusion time for bamlanivimab/etesevimab.
According to Wall Street Journal, Eli Lilly And Co's (NYSE: LLY) said it wouldn't try to claw back past pay from departed finance chief Joshua Smiley. Smiley's resignation wasn't related to fi...
Eli Lilly and Co (NYSE: LLY)'s antibody treatments have received an emergency use authorization from the United States Food and Drug Administration. What Happened: The federal regulator issued...
INDIANAPOLIS, Feb. 9, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for investigational bamlanivimab (LY-CoV555) 700 mg and etesevi...
PRIMECAP Management ( Current Portfolio ) has revealed its portfolio for the fourth quarter. Major trades include a new buy in Morgan Stanley (NYSE:MS) and reductions in Qualcomm Inc. (NASDAQ:...
ABBV vs. LLY: Which Stock Is the Better Value Option?
Eli Lilly said Tuesday Chief Financial Officer Josh Smiley had resigned after allegations about a personal relationship sparked an investigation that found “inappropriate personal communicatio...
Eli Lilly And Co's (NYSE: LLY) Chief Financial Officer Josh Smiley resigned after an independent investigation found inappropriate personal communication with some Lilly employees. The invest...
Eli Lilly and Co. (NYSE: LLY) is shuffling the executive deck on Tuesday after allegations about inappropriate communication arose against Chief Financial Officer Josh Smiley.
Eli Lilly announced that Josh Smiley, its chief financial officer and senior vice president, has resigned after an investigation revealed "inappropriate personal communications" with employees.
American Resources Corporation (NASDAQ:AREC) announced Tuesday that it has engaged technology veteran William E. Smith III to lead the design, build and operation phase of its rare earth and c...
Eli Lilly and Co said on Tuesday its chief financial officer Josh Smiley will step down after an independent investigation found inappropriate personal communication with certain Lilly employees.
Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.
INDIANAPOLIS, Feb. 4, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, March 15, 2021 to provide an update on its Alzheimer's disease program and discus...
Investors are betting this underdog will succeed where even the most reputable of biotech firms have failed.
INDIANAPOLIS, Feb. 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, February 12, 2021. Anne White, sen...
In this article series, we provide a summary of upcoming ex-dividend dates.
They've consistently beaten the market in recent years and they're still growing.
INDIANAPOLIS, Feb. 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has partnered with local health systems to launch dedicated infusion center locations serving central, northern, an...
About LLY
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural m... [Read more...]
| Industry Drug Manufacturers-General | Founded 1876 |
| CEO David Ricks | Employees 35,000 |
| Stock Exchange NYSE | Ticker Symbol LLY |
Financial Performance
In 2020, Eli Lilly's revenue was $24.54 billion, an increase of 9.95% compared to the previous year's $22.32 billion. Earnings were $6.19 billion, a decrease of -25.54%.
Analyst Forecasts
According to 20 analysts, the average rating for Eli Lilly stock is "Buy." The 12-month stock price forecast is 216.14, which is an increase of 4.46% from the latest price.